This work provided evidence that HPV status can be used to predict the effectiveness of PD-1 inhibitors in HNSCC, which is independent of PD-L1 expression and tumor mutation burden, and is probably results from an inflamed immune microenvironment induced by HPV infection (19). The gene discussed is PDCD1; the disease is neoplasm.